N/A
Completed N=301
Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)
Source: ClinicalTrials.gov NCT02637232 ↗Enrolled (actual)
301
Serious AEs
0.4%
Results posted
May 2021
Primary outcomePrimary: Satisfaction Among Patients to Whom Mirvaso®/OnrelteaTM is Prescribed Question — 55; 86; 38; 31 Participants
Summary
The aim of the study is to evaluate the level of satisfaction among patients to whom Mirvaso® / Onreltea TM (trade mark) is prescribed.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Satisfaction Among Patients to Whom Mirvaso®/OnrelteaTM is Prescribed Question |
55; 86; 38; 31; 27 | — |
Eligibility Criteria
Inclusion Criteria
- Patients to whom the physician has already decided to prescribe Mirvaso® /OnrelteaTM according to package insert
Data sourced from ClinicalTrials.gov (NCT02637232). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.